According to the company, the acquisition expands its services portfolio to medical devices – with a staff of around 100 people and facilities including operating rooms for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.
Dr. Jean-François Le Bigot, Chairman and CEO of CiToxLAB Group said the company identified the preclincical CRO as a “strategic target” to position the group as a “more global services player.”
“Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers,” he said.
Drug development and medical devices
Several CROs are preparing for this convergence of drug development and medical devices, as they look to expand offerings into the area – most recently demonstrated with CSSI LifeSciences announcement yesterday.
The company told us the launch of its fully integrated medical device contract research organization is a “logical extension” of its life sciences business.
Additionally, the FDA and EMA recently introduced new guidance and regulations for medical devices and medical device/drug combinations.